HOXA1 and gastric cancer: ‐Blocking HOXA1‐PITX2 interaction by nortriptyline suppresses progression of gastric cancer, highlighting HOXA1/PITX2 axis as a novel therapeutic target for lysosomal exocytosis‐mediated SASP in cancers.